Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial

JAMA Cardiology
Analysis (n=2215) found rivaroxaban monotherapy linked to 38% lower risk of total CV & bleeding events, than combination anticoagulant & antiplatelet therapy (HR 0.62; 95% CI, 0.48-0.80; p < 0.001) and mortality risk after a bleeding event was higher than after a thrombotic event.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services